Annual securities reports (有価証券報告書) filed on EDINET — management narrative only (statistics tables, financial-statement notes, director remuneration and cross-shareholding disclosure are excluded). TSE corporate-governance reports and TDnet are separate documents and are not read here.
JCR Pharmaceuticals Co.,Ltd. 4552
| Cost of capital | no mention mentions it only outside the narrative | matched by rule |
|---|---|---|
| PBR | no mention | matched by rule |
| Metric | no metric named | matched by rule |
| Target | no numeric target | matched by rule |
| Payout | states a numeric policy 「剰余金の配当等につきましては、将来の利益の源泉となる新薬開発や経営体質強化のための内部留保を確保しつつ、業績およびキャッシュ・フローの状況を勘案しながら継続的かつ安定的な配当を行うことを基本方針としており、ご期待に応える株主還元と財務の健全性のバランスを重視し、配当性向につきましては30%を目安としております」ManagementAnalysisOfFinancialPositionOperatingResultsAndCashFlowsTextBlock | matched by rule |
For desks: your watchlist through these questions, kept current each filing season. Custom, from $999+.
Reply with your names